Oculis rings the Nasdaq Iceland opening bell
Oculis became dual-listed on the Nasdaq Iceland Main Market, complementing its existing listing on the Nasdaq Global Market in the U.S. (Nasdaq: OCS).
Oculis rings the Nasdaq Iceland opening bell! 🇮🇸 🔔
Oculis became dual-listed on the Nasdaq Iceland Main Market, complementing its existing listing on the Nasdaq Global Market in the U.S. (Nasdaq: OCS).
Preceding the Iceland listing, Oculis successfully closed an oversubscribed equity financing round of $59 million. This funding round included new Icelandic institutional investors as well as participation from existing investors, thereby extending the cash runway until the second half of 2026 and remain on track for significant catalysts in the innovative pipeline.
Later this quarter, we anticipate the readout from Phase 2b RELIEF trial of OCS-02 in Dry Eyes Disease (DED). 👁
Óskar Fannar Vilmundarson has been appointed Investment Director, Einar Þór Gústafsson has been appointed Investment Director, and Pétur Snær Auðunsson has joined as Analyst.
Brunnur III invests in startups and growth companies, with the goal of supporting strong teams building international companies out of Iceland.
Former Moderna executive Örn Almarsson, PhD, hopes to expand RNA therapeutic targets for autoimmune disease using proprietary lipid chemistry and AI
Exceptional growth for start-up company hopp
The history of Icelandic VC funds and the Icelandic start-up ecosystem.
DTE has successfully managed to close a $16M Series A round in 2023
